- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02634671
Perception of Facial Emotions in Schizophrenia and 22q11 Deletion Syndrome (FaSchi22)
Facial Expression Perception by Intensity in Schizophrenia and 22q11.2 Deletion Syndrome: Neural Electrophysiological Evidence by Means of Fast Periodic Visual Stimulation
Background:
The present study aims to identify the mechanisms underlying the deficit in facial emotion recognition reported both in schizophrenia and the 22q11.2 deletion syndrome, and thus, reveal a distinction between the two disorders. Indeed, despite the clinical overlap between the two syndromes, some of the symptoms appear to be specific to only one of them. In particular, the disturbance of visual functions is specifically observed in the 22q11.2DS. Hence, the difficulties in facial emotion recognition in schizophrenia and in the 22q11.DS are likely accounted by different cognitive impairments. Investigating which mechanisms are disturbed would allow a specialized support for patients.
Our main hypothesis is that the deficit in facial emotion recognition is more related to visual impairments in the 22q11.2DS than in schizophrenia. This hypothesis will be tested in two groups of patients (22q11.2DS and schizophrenic patients) and a control group (healthy subjects) using an experimental paradigm based on electroencephalography (EEG).
A second aim of this study is to determine whether the severity of the two disorders' symptoms is correlated with the cerebral response to facial expressions. To answer this question, a set of clinical and neuropsychological tests will be conducted for each patient.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Methods:
This study will be conducted using visual steady-state visual evoked potentials (SSVEPs). Visual SSVEPs are periodic neural electrophysiological activities that arise in response to fast periodic visual stimulation (FPVS). They will be recorded in response to the periodic presentation of faces, according to an oddball paradigm. While pictures of faces will appear at a 6 Hz rate, only 1 out of 5 will display an emotion, corresponding to a 1.2 Hz oddball frequency. Different emotions will be tested (happiness, sadness, anger, fear and disgust), displayed with different intensities (20%, 60%, 100%). SSVEPs at 6 Hz will reflect general visual mechanisms (in response to a mixture of low-level (i.e., contrast coding) and high-level (i.e., face detection) processes). Importantly, SSVEPs at 1.2 Hz will index the visual mechanisms specifically involved in facial expression perception and their sensitivity to emotion intensity. Both measures will help determine the underlying brain topographies.
Alongside, clinical and neuropsychological tests will be conducted. While the clinical tests will evaluate the severity of the symptoms, the neuropsychological tests will assess different features such as attention, memory, verbal and visuo-spatial abilities. The patients' scores will be linked with their cerebral activity in response to facial expressions.
Outcomes:
To better understand the impairment of facial emotion recognition in schizophrenia and 22q11.2DS and to improve its care.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Aged 15-50 years old
- No psychiatric conditions or comorbidity
- Agreement from parents if participant is underage
- Patients with schizophrenia: diagnosis assessed with DSM5 criteria
- Patients with 22q11.2 DS: diagnosis assessed by genetic tests (CGH- array or FISH)
- No mental delay (IQ>70 according to the fNART)
- No modification of psychotropic treatment during the month before inclusion
Exclusion Criteria:
- Involvement in a current program of social cognition remediation
- Pregnancy
- Substance use disorder (criteria of DSM-5), except for caffeine and tobacco
- Neurologic disorders (vascular, infectious or neurodegenerative)
- Uncorrected visual deficit
- Guardianship
- Medical drugs with cerebral or psychological effect (e.g, corticosteroids)
- Resistance to antipsychotics
- Electroconvulsive therapy in the previous two months
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: 22Q11
24 patients with 22Q11DS to determine whether the severity of the two disorders' symptoms is correlated with the cerebral response to facial expressions.
To answer this question, a set of clinical and neuropsychological tests will be conducted for each patient.
|
The present study aims to identify the mechanisms underlying the deficit in facial emotion recognition reported both in schizophrenia with a control group using an experimental paradigm based on electroencephalography (EEG)
The present study aims to identify the mechanisms underlying the deficit in facial emotion recognition reported both in the schizophrenia and 22q11.2
deletion syndrome with a control group using an experimental paradigm based on electroencephalography (EEG)
|
Other: SCHIZOPHRENIA
24 patients with schizophrenia to determine whether the severity of the two disorders' symptoms is correlated with the cerebral response to facial expressions.
To answer this question, a set of clinical and neuropsychological tests will be conducted for each patient.
|
The present study aims to identify the mechanisms underlying the deficit in facial emotion recognition reported both in the schizophrenia and 22q11.2
deletion syndrome with a control group using an experimental paradigm based on electroencephalography (EEG)
The present study aims to identify the mechanisms underlying the deficit in facial emotion recognition reported both in the 22q11.2
deletion syndrome with a control group using an experimental paradigm based on electroencephalography (EEG)
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Steady-state visual evoked potentials (SSVEP) recorded during fast periodic visual stimulation (FPVS).
Time Frame: SSVEPs will be recorded during 20 sequences of emotional faces pictures. As each sequence lasts 80s, the EEG recording will be approximately 30-minutes-long.
|
SSVEPs arise in response to the periodic presentation of emotional faces.
They are analyzed in the frequency domain.
Two types of responses are expected: the general visual response (6 Hz and its harmonics) and the expression-specific response (1.2 Hz and its harmonics).
Both responses will be compared across the different groups.
|
SSVEPs will be recorded during 20 sequences of emotional faces pictures. As each sequence lasts 80s, the EEG recording will be approximately 30-minutes-long.
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: DEMILY CAROLINE, PH, Centre régional de dépistage et de prises en charge des troubles psychiatriques d'origine génétique Pôle Ouest LE VINATIER HOSPITAL
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2015-A01247- 42
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Schizophrenia
-
Organon and CoCompletedSchizophrenia, Paranoid | Schizophrenia, Disorganized | Schizophrenia, Undifferentiated
-
Organon and CoCompletedSchizophrenia, Paranoid | Schizophrenia, Disorganized | Schizophrenia, Undifferentiated
-
Bradley LegaRecruiting
-
All India Institute of Medical Sciences, BhubaneswarRecruitingTreatment Resistant SchizophreniaIndia
-
King's College LondonSouth London and Maudsley NHS Foundation TrustRecruitingTreatment-resistant Schizophrenia | Healthy Controls | Treatment-responsive SchizophreniaUnited Kingdom
-
University of Sao PauloUnknownRefractory Schizophrenia | Super Refractory SchizophreniaBrazil
-
Ohio State UniversityRecruitingTreatment-resistant SchizophreniaUnited States
-
University Hospital, BrestRecruitingSchizophrenia | Schizophrenia Prodromal | Schizophrenia, ChildhoodFrance
-
NYU Langone HealthNot yet recruitingTreatment-resistant SchizophreniaUnited States
-
Johns Hopkins UniversityNational Institute of Mental Health (NIMH)RecruitingTreatment-resistant SchizophreniaUnited States
Clinical Trials on schizophrenia
-
Johns Hopkins Bloomberg School of Public HealthNational Institute of Mental Health (NIMH)Completed
-
University Hospital, Strasbourg, FranceTerminated
-
University of Alabama at BirminghamJanssen Research & Development, LLCCompletedPrediction of Relapse in Schizophrenia/Schizoaffective Disorder With Smartphones and On-body SensorsSchizophrenia | Schizoaffective DisorderUnited States
-
Hôpital le VinatierCompleted
-
University Hospital, GrenobleUnknown
-
Lithuanian University of Health SciencesRecruitingSchizophrenia | Cognitive Deficit | Negative Symptoms in Schizophrenia | Depressive Symptoms Due to Primary Psychotic Disorder (Diagnosis)Lithuania
-
Beijing HuiLongGuan HospitalCompletedSchizophrenia | Major Depressive DisorderChina
-
Bezmialem Vakif UniversityCompleted
-
US Department of Veterans AffairsCompletedSchizophrenia | Schizophrenic DisorderUnited States
-
Rakitzi, StavroulaRecruiting